Get the Stockscreener App
0.6978
0.81%
-0.003
Bioatla Inc stock is traded at $0.6978, with a volume of 263.24K.
It is down -0.81% in the last 24 hours and up +0.19% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.6948
Open:
$0.7068
24h Volume:
263.24K
Relative Volume:
0.27
Market Cap:
$40.73M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.2694
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-9.32%
1M Performance:
+0.19%
6M Performance:
+41.75%
1Y Performance:
-64.10%
1-Day Range:
$0.674
$0.7202
1-Week Range:
$0.6611
$0.80
52-Week Range:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.6936 | 40.80M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.49 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.05 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
820.89 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.47 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Is BioAtla Inc. a candidate for recovery play2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Sentiment analysis tools applied to BioAtla Inc.2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Why BioAtla Inc. stock is favored by top institutions2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Analyzing BioAtla Inc. with risk reward ratio chartsLayoff News & Verified Short-Term Plans - newser.com
Will BioAtla Inc. continue its uptrendQuarterly Profit Review & Consistent Income Trade Ideas - newser.com
How supply chain issues affect BioAtla Inc. stockAnalyst Upgrade & Weekly High Conviction Ideas - newser.com
Chart overlay techniques for tracking BioAtla Inc.Gold Moves & Low Drawdown Trading Strategies - newser.com
Measuring BioAtla Inc.’s beta against major indicesWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com
What moving averages say about BioAtla Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
What to do if you’re stuck in BioAtla Inc.Weekly Trade Report & Weekly Breakout Stock Alerts - newser.com
Why BioAtla Inc. stock is a value investor pickWeekly Risk Summary & Advanced Technical Signal Analysis - Fundação Cultural do Pará
BioAtla’s Phase 1 Study on BA3182: A New Hope for Advanced Adenocarcinoma - TipRanks
Can BioAtla Inc. stock sustain institutional interest2025 Big Picture & Capital Protection Trade Alerts - Fundação Cultural do Pará
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.68%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):